Navigation Links
New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility

cant 44% relative risk reduction in VTE events observed for extended-duration prophylaxis with enoxaparin vs. placebo for the primary endpoint (2.8% vs. 4.9%; p=0.0011) was associated with a reduction in symptomatic VTE by 73% (0.3% vs. 1.1%; p=0.0044) and asymptomatic proximal DVT by 34% (2.5% vs. 3.7%; p=0.0319). No statistically significant differences were observed for symptomatic pulmonary embolism (PE) or fatal PE. The statistically significant relative risk reduction of VTE observed with enoxaparin at 38 days was maintained at 90 days (3.0% vs. 5.2%; p=0.0015).

Victor F. Tapson, MD, Professor of Medicine, Director, Center for Pulmonary Vascular Disease, Division of Pulmonary and Critical Care, Duke University Medical Center, Durham, NC, and a lead investigator of the EXCLAIM study said :"What the trial results showed is that patients do not leave their risk for VTE at the door when they leave the hospital. With continued prophylaxis, Lovenox(R) statistically significantly reduced the risk by 44% in acutely ill medical patients with prolonged immobility."

In comparison with placebo, the rate of major bleeding was statistically significantly higher in the extended enoxaparin arm (0.6% vs. 0.15%, p=0.019), but the overall event rate was low. There was no difference in all-cause mortality between extended enoxaparin vs. placebo at 6 months (10.1% vs. 8.9%; p=0.18).

"EXCLAIM is the first study to assess the benefit of extended thromboprophylaxis in acutely ill medical patients with reduced mobility and to demonstrate the clinical benefit of 5 weeks enoxaparin treatment versus 10 days in this patient population" said Professor Russell Hull from the University of Calgary, Canada and Chair of the Steering Committee for the EXCLAIM study

"Similarly to the initial demonstration of the benefit of thromboprophylaxis for acutely ill medical patients, first established by the MEDENOX trial, the EXCLAIM study should be a landmark trial in advanci
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
(Date:9/18/2014)... 18, 2014  PRO-DEX, INC. (NasdaqCM: PDEX) today announced ... full-year ended June 30, 2014. Quarter ... ended June 30, 2014 increased $492,000, or 18%, to ... ended June 30, 2013, due primarily to an increase ... from the Company,s largest customer, partially offset by an ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "China PTCA Balloon Market Investment Report, 2014-2016" ... balloon, as a indispensable medical device in percutaneous coronary ... for stent, but also as a device for pre-/post-stent ... closely related to that of PCI. As ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3
... part of the eighth annual DVT (deep-vein thrombosis) Awareness Month, ... of DVT and its risk factors among patients with co-morbid ... respiratory and obesity patients.   DVT remains the ... deaths may be due to PE (pulmonary embolism).(1)  This is ...
... Ill., March 9, 2011 Hospira, Inc. (NYSE: ... announced U.S. Food and Drug Administration (FDA) approval of docetaxel. ... Hospira expects to launch the product later this month. ... variety of cancers. In 2010, U.S. sales of Taxotere were ...
Cached Medicine Technology:Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 2Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 3Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 4Hospira Announces U.S. Approval of Generic Docetaxel 2
(Date:9/19/2014)... also known as Johne,s disease, is caused by ... (MAP). In Austria, there is a legal obligation ... and causes treatment-resistant diarrhoea and wasting among affected ... for commercial farms. The animals produce less milk, ... other conditions such as udder inflammation. , ...
(Date:9/19/2014)... 19, 2014 The Canton Group, Baltimore’s leading ... website for the Xaverian Brothers. The new site aligns ... encourage and edify one another through a life of Gospel ... summons “to manifest God’s care and compassionate love to the ... was developed using a responsive web design, which allows users ...
(Date:9/19/2014)... Outsourcing services provider Profit By RPO has bagged a huge ... HR outsourcing services in India. , " Profit By RPO ... act as a talent acquisition and transformation partner. Under the ... 3 locations in India in the next four months," the ... win for us and we are delighted to collaborate with ...
(Date:9/19/2014)... The dentist at Encino Esthetic Dental ... Throughout the month of September, new patients will be able ... just $69. A complimentary home teeth whitening kit will be ... gums checked and meet the team at Encino Esthetic Dental ... protect oral health. According to the American Dental Association, biannual ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Women of ... to maintain better oral care and visit the dentist ... Centers for Disease Control and Prevention. Researchers found ... Mexican-American, as well as those with lower income and ... Oral disease, with symptoms such as cavities or ...
Breaking Medicine News(10 mins):Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:Xaverian Brothers Partner with The Canton Group to Launch New Website 2Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2Health News:Encino Esthetic Dental Group is Now Offering a Special Promotion for New Patients 2Health News:Oral Health in Women of Childbearing Age Needs Improvement 2
... effects in patients with high-grade glioma from chemoradiation may ... radiation oncologists at the Kimmel Cancer Center at ... the April issue of the British Journal ... occurrence of early side effects, such as fatigue and ...
... prohibition against testosterone therapy in men with untreated or ... study published in The Journal of Urology . ... a history of prostate cancer, even if treated and ... to the belief that testosterone activated prostate cancer growth, ...
... secure emotional relationship with their parents, and particularly their mothers, ... , according to new research. The study suggests that ... have at least 30 percent higher odds for obesity by ... researchers accounted for other family-related factors that could provide alternative ...
... Dieters are so involved with trying to eat virtuously that they ... labeled as healthy, according to a new study in the ... names can work to their disadvantage. "Keeping your weight-loss goal ... you are careful to avoid pasta selections and instead order from ...
... INDIANAPOLIS Jason S. Meyer, Ph.D., assistant professor of ... University Indianapolis, will be honored by the largest eye ... which one day may lead to reversal of blindness ... of the retina. The Association for Research ...
... smoke a cigarette may not be enough to protect the ... to a new study in the American Journal of ... Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA ... recognized category of tobacco smokeknown as "thirdhand smoke"can have as ...
Cached Medicine News:Health News:Minimizing side effects from chemoradiation could help brain cancer patients live longer 2Health News:Study suggests another look at testosterone-prostate cancer link 2Health News:Study suggests another look at testosterone-prostate cancer link 3Health News:Quality of parent-toddler relationship could affect risk for childhood obesity 2Health News:Quality of parent-toddler relationship could affect risk for childhood obesity 3Health News:Quality of parent-toddler relationship could affect risk for childhood obesity 4Health News:When a salad is not a salad: Why are dieters easily misled by food names? 2Health News:IUPUI faculty member to receive national innovative vision research award 2Health News:LA BioMed study finds 'thirdhand smoke' poses danger to unborn babies' lungs 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: